title: Effects of verteporfin therapy on central visual field function.
abstract: OBJECTIVE
  To evaluate the effect of photodynamic therapy with verteporfin on the maintenance of central visual field function.
  
  
  METHODS
  Randomized controlled clinical trial.
  
  
  METHODS
  Forty-six consecutive patients with subfoveal choroidal neovascularization (CNV) caused by age-related macular degeneration including a classic component were randomly assigned. Thirty-three participants received standard verteporfin therapy, and 13 received placebo and laser treatment.
  
  
  METHODS
  The trial was performed as a single-center, double-masked study. Patients were examined before therapy and continuously in 3-month intervals during 2 years of follow-up. A scanning laser ophthalmoscope (SLO) was used to perform macular microperimetry. Absolute and relative scotomas were documented at each visit, and size was measured in square millimeters.
  
  
  METHODS
  The change in size of central scotoma in the verteporfin group compared with the placebo group.
  
  
  RESULTS
  An absolute scotoma was seen in 88%, and a relative scotoma was seen in 100% of eyes before therapy. Absolute defects were associated with the classic CNV component localized angiographically. In the verteporfin group, the absolute scotoma grew from 2.5 mm(2) at baseline to a final size of 7.3 mm(2) at month 24. In the placebo group, the mean lesion size of the absolute scotoma enlarged from an initial size of 2.7 mm(2) to 31.5 mm(2) after 24 months. The relative scotoma increased from 7.9 mm(2) at baseline to 20.8 mm(2) at month 24 in the verteporfin group, whereas a progression from 8.5 mm(2) initially to 48.3 mm(2) at the final presentation was measured in the placebo group. Statistical analysis showed that both the mean absolute and relative scotoma sizes were significantly smaller in the verteporfin group than the placebo group for all intervals from 6 to 24 months (P<0.001).
  
  
  CONCLUSIONS
  Documentation of macular function with SLO perimetry demonstrated a significant benefit of verteporfin therapy for the preservation of the central visual field. Absolute and relative scotoma sizes remained smaller after therapy. This may influence reading ability and visual rehabilitation.
authors.affiliation: Department of Ophthalmology, University of Schleswig-Holstein, Luebeck, Germany.
authors.forename: Ursula M
authors.initials: UM
authors.lastname: Schmidt-Erfurth
authors.forename: Hanno
authors.initials: H
authors.lastname: Elsner
authors.forename: Naim
authors.initials: N
authors.lastname: Terai
authors.forename: Anke
authors.initials: A
authors.lastname: Benecke
authors.forename: Gerlinde
authors.initials: G
authors.lastname: Dahmen
authors.forename: Stephan M
authors.initials: SM
authors.lastname: Michels
mesh_terms: D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D004311:Double-Blind Method; D005451:Fluorescein Angiography; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D009887:Ophthalmoscopy; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D012160:Retina / Q000503:physiopathology*; D012607:Scotoma / Q000175:diagnosis / Q000503:physiopathology*; D000077362:Verteporfin; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology*
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin